文献速递浆细胞疾病造血干细胞移植与细胞治疗

复发/难治性多发性骨髓瘤患者接受Teclistamab治疗时细胞因子释放综合征的模式:既往是否接受过T细胞重定向治疗的影响

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性研究纳入72例完成Teclistamab阶梯剂量阶段的复发/难治性多发性骨髓瘤患者,比较既往接受过与未接受过T细胞重定向治疗两组的细胞因子释放综合征(CRS)发生率。既往暴露组CRS发生率为37%(n=10),未暴露组为80%(n=36),差异有统计学意义(P=.0004);多因素分析显示未暴露组CRS发生风险约为暴露组的4倍(95%CI 1.40-14.90,P=.0002)。

要点

  • 既往接受过T细胞重定向治疗的患者,Teclistamab阶梯剂量期间CRS发生率显著更低。
  • 未接受过T细胞重定向治疗者CRS发生风险约为既往暴露者的4倍。
  • 该观察结果有助于优化Teclistamab的CRS预防策略。

核心结论

  • 本研究中,既往接受过T细胞重定向治疗降低了Teclistamab阶梯剂量阶段的CRS风险。

研究设计与样本

  • 回顾性病历审查,纳入2022年11月至2023年11月期间完成Teclistamab阶梯剂量阶段的患者。
  • 共纳入72例患者,按既往是否接受过T细胞重定向治疗分为2组:暴露组27例,未暴露组45例。
  • 主要目标为比较两组CRS发生率的差异,并采用单因素和多因素logistic回归分析CRS与既往T细胞重定向治疗的关系。

主要发现

  • 暴露组CRS发生率为37%(n=10),未暴露组为80%(n=36),暴露组显著低于未暴露组(P=.0004)。
  • 多因素logistic回归分析显示,未暴露组CRS发生风险约为暴露组的4倍(95%CI 1.40-14.90,P=.0002)。

临床怎么用

  • 作者认为,该观察结果将有助于优化Teclistamab的CRS预防策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Teclistamab (Tec) is a first-in-class BCMA × CD3 bispecific T-cell engager antibody approved for treating multiple myeloma progressing after at least 4 lines of therapy. The objective of this study was to evaluate the rate of cytokine release syndrome (CRS) in patients who were treated with commercial Tec and had prior exposure to other T-cell redirection therapies. A retrospective chart review was performed to identify patients who completed the Tec step-up dosing phase between November 2022 and November 2023. Patients were divided into 2 cohorts based on prior exposure to T-cell redirection therapy (cohort 1: T-cell redirection therapy experienced; cohort 2: T-cell redirection therapy naïve). The primary objective was to compare the differences in the rates of CRS between the 2 cohorts. Univariate and multivariate logistic regression analyses were performed to assess the association between CRS rates with Tec and prior treatment with T-cell redirection therapy. A total of 72 patients were included in the analysis (27 in cohort 1 and 45 in cohort 2). The CRS rates were significantly lower in cohort 1 (37%, n = 10) compared with cohort 2 (80%, n = 36; P = .0004). Based on multivariate logistic regression analysis, patients without prior exposure to T-cell redirection therapy (cohort 2) had about a fourfold increase in the incidence of CRS (95% confidence interval, 1.40-14.90; P = .0002) with Tec. In our study, prior exposure to T-cell redirection therapy reduced the risk of CRS with Tec during the step-up dosing phase. This observation will allow for the optimization of CRS prophylactic strategies for Tec.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hamadeh IS, Shekarkhand T, Rueda C, et al. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy. Blood Adv. 2024. PMID: 38598713. doi:10.1182/bloodadvances.2024012724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。